Oncology Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-VNCAML-220206. Date of Preparation: November 2022.

      Downloadable VENCLYXTO resources

      Video library

      Haematology experts provide their opinions on key topics in the treatment of AML

      VIALE-A: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

      Dr. Richard Dillon provides an overview of the VIALE-A trial of azacitidine and venetoclax in previously untreated acute myeloid leukemia patients who were ineligible for intensive chemotherapy

      Management strategies and real-world experience with venetoclax in first-line AML

      Watch Dr. Richard Dillon discuss his experience using venetoclax in clinical practice. He explains how he manages venetoclax in first-line AML

      Expert opinion: Using venetoclax in first-line chemotherapy-ineligible AML

      Watch Professor Nigel Russell discuss venetoclax treatment in first-line AML patients ineligible for intensive chemotherapy

      VENCLYXTO AML PRESCRIBING INFORMATION
      VENCLYXTO CLL PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCAML-230083. Date of preparation: October 2023.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.